2-(3-氨基苯氧基)-N,N-二甲基乙酰胺 | 184944-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(3-氨基苯氧基)-N,N-二甲基乙酰胺
• 英文名称: 2-(3-aminophenoxy)-N,N-dimethylacetamide
• CAS: 184944-88-5
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD09046918
• 分子量: 194.233
• InChiKey: ORVOZEIZAGYCHU-UHFFFAOYSA-N

物化性质

• 沸点：
  379.7±22.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  三光气 、 2-(3-amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-phenylacetamide 、 2-(3-氨基苯氧基)-N,N-二甲基乙酰胺 在 三乙胺 作用下， 生成 2-[3-[[3-[2-(dimethylamino)-2-oxoethoxy]phenyl]carbamoylamino]-2,4-dioxo-5-phenyl-1,5-benzodiazepin-1-yl]-N-phenyl-N-propan-2-ylacetamide
  参考文献：
  名称：

  Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II):  Optimization of the C3 Amino Substituent

  摘要：

  Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC(50) = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist; of CCK-8 (pA(2) = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.

  DOI：

  10.1021/jm9601664
• 作为产物：
  描述：

  N,N-dimethyl-2-(3-nitrophenoxy)acetamide 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 2-(3-氨基苯氧基)-N,N-二甲基乙酰胺
  参考文献：
  名称：

  Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II):  Optimization of the C3 Amino Substituent

  摘要：

  Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC(50) = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist; of CCK-8 (pA(2) = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.

  DOI：

  10.1021/jm9601664

文献信息

• (7H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2597098A1

  公开（公告）日：2013-05-29

  Inhibitors of LIM kinase 2 of the following formula are disclosed, along with pharmaceutical compositions comprising them and methods of their use, in particular for treatment of inflammatory and cancerous and ocular diseases. X is O or NRA; A is cycloalkyl, aryl or heterocyclyl; RA is hydrogen, cyano, nitro, RA1, SO2RA1 or SO2N(RA1)2; each RB is independently hydrogen or alkyl. The other variables are as defined in the claims.

  本研究公开了下式的 LIM 激酶 2 抑制剂，以及包含这些抑制剂的药物组合物和使用方法，尤其是用于治疗炎症、癌症和眼部疾病的方法。 X 是 O 或 NRA； A 是环烷基、芳基或杂环基； RA 是氢、氰基、硝基、RA1、SO2RA1 或 SO2N(RA1)2 每个 RB 独立地为氢或烷基。 其他变量如权利要求中所定义。
• (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2188289B1

  公开（公告）日：2015-10-28
• [EN] KINASE INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE KINASE, COMPOSITIONS LES CONTENANT ET PROCÉDÉS D'UTILISATION
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2009021169A2

  公开（公告）日：2009-02-12

  Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions com πsin them and methods of their use. X is O or NRA; Y is O, NRR, or C(RR)2; A is cycloalkyl, aryl or hctcrocyclc; RA is hydrogen, cyano, nitro, RA1, SO2RA1, SO2NRA1, or SO2N(RA1)2;